Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NH › Berlin › NPI 1386680593
Physician

Androscoggin Valley Hospital, INC.

Androscoggin Valley Hospital, INC. was paid $8.28M by Medicaid between Jan 2018 and Dec 2024, across 149 billing codes. Its largest line is 99283, emergency room visit (moderate) — 19% of everything it billed.

33Billing provider infoANDROSCOGGIN VALLEY HOSPITAL, INC.
BERLIN, NH 03570
33aNPI1386680593assigned 06/22/2006
33bProvider typeFamily Medicine Physician
28Total paid$8.28M
24GClaims185,929
24DCodes billed149
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Family Medicine Physician providers in New Hampshire

Rank by total paid#1 of 65
Median peer was paid$17K
This provider vs. median484×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201828,004$674K
201935,651$943K
202033,890$1.57M
202140,292$2.01M
202231,020$2.08M
202311,532$619K
2024incomplete5,540$387K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 19% 16,953 8,963 $1.58M
99282 Emergency department visit for the evaluation and management, low to moderate severity 17% 13,049 7,930 $1.42M
74177 Computed tomography, abdomen and pelvis; with contrast material 8.6% 563 389 $713K
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 7.8% 7,436 4,038 $649K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 5.1% 5,359 1,369 $423K
G0378 Hospital observation service, per hour 3.7% 414 226 $308K
70450 Computed tomography, head or brain; without contrast material 3.4% 1,035 570 $282K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml 2.5% 2,426 1,728 $210K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 2.4% 2,582 2,180 $202K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 2.1% 2,492 1,497 $178K
99281 Emergency department visit for the evaluation and management, self-limited or minor 2.1% 2,069 1,429 $173K
71046 Radiologic examination, chest; 2 views 1.9% 2,537 1,432 $155K
137 more codes
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.7% 1,406 $143K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) 1.6% 2,069 $134K
96375 Therapeutic injection; each additional sequential IV push 1.2% 1,959 $103K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.2% 2,400 $95K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 1.0% 2,302 $86K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.0% 2,262 $84K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 2,738 $82K
99285 Emergency room visit (most serious) <1% 740 $79K
96361 Intravenous infusion, hydration; each additional hour <1% 420 $70K
73562 <1% 660 $67K
71045 Radiologic examination, chest; single view <1% 1,438 $62K
80053 Comprehensive metabolic panel <1% 10,781 $50K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 2,249 $50K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 988 $48K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 1,636 $44K
73610 <1% 309 $40K
77067 Screening mammography, bilateral, including computer-aided detection <1% 83 $40K
73030 <1% 455 $39K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 11,393 $37K
84443 Thyroid stimulating hormone (TSH) <1% 3,901 $36K
73630 <1% 361 $33K
64635 <1% 67 $30K
80061 Lipid panel <1% 2,384 $25K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed <1% 1,069 $24K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 1,037 $22K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 1,035 $21K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 583 $21K
87631 <1% 293 $20K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 164 $20K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 27 $19K
97161 <1% 195 $17K
99214 Doctor's office visit, returning patient (more involved) <1% 1,797 $17K
20553 <1% 495 $16K
72100 <1% 106 $16K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 310 $14K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r <1% 165 $13K
83735 <1% 5,017 $13K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 4,128 $12K
J3490 Unclassified drugs <1% 2,625 $12K
85027 <1% 2,166 $11K
64636 <1% 62 $10K
36415 Collection of venous blood by venipuncture <1% 18,015 $10K
64640 <1% 76 $9K
87086 Culture, bacterial; quantitative colony count, urine <1% 2,182 $8K
J1030 Injection, methylprednisolone acetate, 40 mg <1% 1,781 $7K
87081 <1% 1,517 $7K
G0260 Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography <1% 14 $7K
83036 Hemoglobin; glycosylated (A1C) <1% 1,027 $7K
73130 <1% 50 $7K
84484 <1% 2,302 $6K
80048 Basic metabolic panel (calcium, ionized) <1% 1,180 $6K
83655 <1% 548 $6K
77063 Screening digital breast tomosynthesis, bilateral <1% 83 $6K
80306 <1% 971 $5K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 217 $5K
81001 <1% 3,398 $5K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 113 $4K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 222 $4K
71250 <1% 22 $4K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 77 $4K
82607 <1% 532 $4K
74018 <1% 30 $4K
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies <1% 199 $4K
83690 <1% 1,175 $4K
20611 <1% 43 $4K
73110 <1% 23 $3K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 1,712 $3K
85610 <1% 2,224 $3K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 380 $3K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 805 $3K
99213 Doctor's office visit, returning patient (routine) <1% 487 $3K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 53 $3K
86140 <1% 1,000 $3K
74019 <1% 31 $3K
87077 <1% 509 $3K
81003 <1% 2,095 $2K
82570 <1% 587 $2K
96376 <1% 47 $2K
97162 <1% 28 $2K
A9576 Injection, gadoteridol, (prohance multipack), per ml <1% 15 $2K
87186 <1% 406 $2K
82043 <1% 425 $2K
81025 <1% 406 $2K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 1,691 $2K
83880 <1% 176 $2K
87430 <1% 193 $2K
86738 <1% 165 $1K
A9579 Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml <1% 20 $1K
87040 <1% 380 $1K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 64 $1K
82728 <1% 148 $1K
83605 <1% 342 $1K
J1040 Injection, methylprednisolone acetate, 80 mg <1% 127 $1K
76942 <1% 18 $1K
84702 <1% 76 $934.46
84439 <1% 121 $904.11
85652 <1% 519 $886.51
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 248 $781.51
86850 <1% 119 $662.74
85651 <1% 348 $625.36
82746 <1% 68 $604.46
36416 <1% 160 $573.18
83540 <1% 119 $563.60
80050 General health panel <1% 66 $547.96
83550 <1% 80 $513.99
93010 Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only <1% 796 $418.64
87070 <1% 69 $384.90
82248 <1% 141 $333.48
0296T <1% 15 $263.50
82565 <1% 113 $246.64
82150 <1% 73 $237.13
84703 <1% 62 $235.83
99215 Doctor's office visit, returning patient (complex) <1% 14 $203.58
82947 <1% 63 $200.42
86592 <1% 80 $198.31
J3010 Injection, fentanyl citrate, 0.1 mg <1% 270 $194.67
99442 <1% 33 $168.00
86803 <1% 13 $164.18
82465 <1% 40 $160.20
85379 <1% 25 $145.79
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 35 $132.11
86901 <1% 102 $126.83
86900 <1% 102 $126.83
84145 <1% 16 $118.69
86038 <1% 18 $113.30
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 143 $105.68
87340 <1% 14 $100.21
87205 <1% 60 $98.65
85730 <1% 41 $98.29
82044 <1% 14 $52.80
85007 <1% 15 $24.48
J2270 Injection, morphine sulfate, up to 10 mg <1% 22 $20.42
85018 <1% 15 $15.35
S9982 Medical records copying fee, per page <1% 24 $12.00
83721 <1% 16 $8.79
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals 0% 19 $0.00
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 21 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialLANDRY, SUZANNE (VP OF COMPLIANCE AND RISK MANAGMENT)
Same official

Other billing entities under LANDRY, SUZANNE

Full network →
ProviderLocationPaid
Weeks Medical CenterLancaster, NH$3.48M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.